Zymeworks completes its $929 million acquisition of Theravance Biopharma, adding a 35% US profit share in revefenacin (Yupelri) and a 20% share of any future ampreloxetine deal to its royalty-driven …
Zymeworks completes its $929 million acquisition of Theravance Biopharma, adding a 35% US profit share in revefenacin (Yupelri) and a 20% share of any future ampreloxetine deal to its royalty-driven …
A committee of Conitec, Brazil’s health technology assessment body, provisionally recommended ViiV’s HIV-prevention injection at its proposed price of about R$6,660 a year, while Brazil offered Gilead roughly a third …
You must be logged in to post a comment.